首页> 外文期刊>Aesthetic surgery journal >Evaluation of a novel high-intensity focused ultrasound device for ablating subcutaneous adipose tissue for noninvasive body contouring: safety studies in human volunteers.
【24h】

Evaluation of a novel high-intensity focused ultrasound device for ablating subcutaneous adipose tissue for noninvasive body contouring: safety studies in human volunteers.

机译:一种新型高强度聚焦超声设备的评估,该设备可消融皮下脂肪组织,实现无创人体轮廓:人类志愿者的安全性研究。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: High-intensity focused ultrasound (HIFU) is an energy-based medical technology with many clinical applications. A device under clinical investigation in the United States (LipoSonix; Medicis Technologies Corporation, Bothell, Washington) uses HIFU to reduce localized deposits of abdominal adipose tissue. OBJECTIVES: The authors describe the results from their clinical trial investigating the safety of this HIFU device in human patients. METHODS: Over the course of three studies evaluating the safety of the HIFU device for ablating human subcutaneous adipose tissue (SAT), 152 healthy patients were treated with total HIFU energy doses of 47 to 331 J/cm(2)), including patients who presented for elective abdominoplasty and underwent treatment to areas identified for subsequent excision. The safety of each treatment regimen was confirmed before the energy levels were raised. Abdominoplasty was performed up to 14 weeks following the HIFU procedure, and a pathologist performed histopathological analyses of excised tissues. Safety evaluations included an assessment of clinical chemistry and hematology profiles, physical examinations, and adverse events. RESULTS: Posttreatment ultrasound confirmed that the HIFU effects were limited to targeted SAT layers. Histopathology revealed well-demarcated disruption of adipocytes within the targeted SAT. Phagocytosis of released lipids and cellular debris occurred after 14 to 28 days. Phagocytized lipids underwent normal hepatic metabolism. Healing progressed normally and was 95% complete after eight to 14 weeks. Adverse events consisted primarily of temporary treatment discomfort, edema, erythema, dysesthesia, and ecchymosis. There were no changes in clinical laboratory parameters, and no serious device-related adverse events occurred. Optimal clinical outcomes were achieved with lower energy levels, which provided beneficial effects with the least amount of discomfort. CONCLUSIONS: HIFU appears to provide a safe means for removing and remodeling unwanted deposits of abdominal SAT.
机译:背景:高强度聚焦超声(HIFU)是一种基于能量的医疗技术,具有许多临床应用。在美国进行临床研究的设备(LipoSonix;华盛顿州博塞尔的Medicis Technologies Corporation)使用HIFU减少腹部脂肪组织的局部沉积。目的:作者描述了他们研究这种HIFU设备对人类患者的安全性的临床试验结果。方法:在三项评估HIFU消融人体皮下脂肪组织(SAT)安全性的研究中,对152名健康患者进行了HIFU总能量剂量为47至331 J / cm(2)的治疗,其中包括提出进行选择性腹部成形术,并在确定的随后切除区域进行治疗。在提高能量水平之前,已确认每种治疗方案的安全性。 HIFU手术后长达14周进行了腹部成形术,病理学家对切除的组织进行了组织病理学分析。安全评估包括对临床化学和血液学特征,身体检查和不良事件的评估。结果:超声处理后证实,HIFU的作用仅限于靶向SAT层。组织病理学揭示了靶向SAT中脂肪细胞的界限清楚。 14至28天后发生释放脂质和细胞碎片的吞噬作用。吞噬的脂质经历了正常的肝代谢。愈合进展正常,在8到14周后恢复了95%。不良事件主要包括临时治疗不适,水肿,红斑,感觉异常和瘀斑。临床实验室参数没有变化,也没有发生与器械相关的严重不良事件。较低的能量水平可实现最佳的临床结果,从而以最小的不适感提供有益的效果。结论:HIFU似乎为去除和重塑腹部SAT不需要的沉积物提供了一种安全的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号